Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

E 1040

Known as: E-1040, E1040 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1992
1992
SCE-2787, a new cephalosporin having a condensed azolium moiety in the 3 position and an aminothiadiazolyl group in the 7 beta… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
1992
1992
The synthesis and in vitro antibacterial activity of a series of 7-[(Z)-2-aminoaryl-2-oxyiminoacetamido]-3-ammoniomethyl++ +-3… Expand
1992
1992
The bactericidal activity of cefclidin (E1040), a new cephalosporin, against Pseudomonas aeruginosa was compared with that of… Expand
1992
1992
Cefclidin (E1040), which has an aminothiadiazolyl group in the 7 beta-side chain, showed about four-fold higher activity against… Expand
  • table 1
  • table 2
  • table 4
  • table 5
  • figure 2
1991
1991
E-1040, a new parenteral fourth-generation cephalosporin, was tested against greater than 600 bacteremic pathogens and compared… Expand
Highly Cited
1990
Highly Cited
1990
Seven extended-spectrum beta-lactamases related to TEM and four enzymes derived from SHV-1 were transferred to a common… Expand
  • table 1
  • table 2
  • table 3
  • table 5
  • table 6
1990
1990
On the basis of preliminary in vitro data, we evaluated E-1040, a new cephalosporin, against 188 cystic fibrosis (CF) sputum… Expand
  • table 1
  • figure 1
1990
1990
E1040 is a new parenteral cephalosporin with a broad antibacterial spectrum and potent activity against Gram-negative bacteria… Expand
1988
1988
E1040 is a new parenteral cephalosporin with a broad antibacterial spectrum and potent antipseudomonal activity. The compound was… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
1988
1988
The in vitro activity of E-1040 [(6R,7R)-3-[(4-carbamoyl-1-quinuclidinio)methyl]-7-[2-(5-amino-1,2 ,4- thiadiazol-3-yl)-(Z)-2… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2